XNAS
ASND
Market cap16bUSD
Oct 30, Last price
251.27USD
1D
-0.68%
1Q
3.02%
Jan 2017
1,141.45%
IPO
1,156.35%
Name
Ascendis Pharma A/S
Chart & performance
P/E
—
P/S
21.37
EPS
—
Vol. 1Y
38.82%
Shs. 5Y
3.67%
Rev. 5Y
150.93%
Div Yld LY
—
Div Yld TTM
—
Revenues
692m
+90.22%
Net income
-219m
L-42.07%
CFO
52m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Key people
Independent Chairman of the Board · since 2021
Flemming Jensen
Executive Vice President, Product Supply and Quality · since 2023
Aimee Shu
Executive Vice President, Chief Medical Officer · since 2024
Stina Singel
Executive Vice President, Head of Clinical Development, Oncology · since 2023
Kennett Sprogoee
Executive Vice President, Head of Innovation and Research · since 2023
Donovan Wu
Executive Vice President, U.S. President · since 2025
Mads Bodenhoff
Senior Vice President, Head of Finance and Principal Accounting Officer · since 2024
Lotte Soenderbjerg
Executive Vice President, Chief Administrative Officer, Member of the Executive Board · since 2023
Michael Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board · since 2023
Jan Mikkelsen
President, Chief Executive Officer, Executive Director, Member of the Executive Board · since 2007
Scott Smith
Chief Financial Officer, Executive Vice President, Member of the Executive Board · since 2025
Independent Director · since 2017
Independent Director · since 2022
Lars Holtug
Independent Director · since 2018
Siham Imani
Independent Director · since 2022
Headquarters & legal address
Tuborg Boulevard 12
Hellerup 2900
DK
Hellerup 2900
DK
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||